There is also some evidence, such as asymmetric cross-tolerance (Pasternak, 2001) and tolerance-rescue studies (He et al., 2002), to suggest that mechanisms of tolerance may differ for different types of agonist
basal insulin cut from 47 to 8-20 IU replacing basal-bolus (SURPASS-6)
PMID: 12217624
still, for most people semaglutide should be good enough 1 Like Neo September 8, 2024, 8:26pm #5 RapAdmin: tested in the ITP program They should something in this broader family, but issues in the past has been needs to be pill/food based and not subcutaneous injections 1 Like Neo September 8, 2024, 8:27pm #6 AlexKChen: widely available on various peptide sites now Any sense of this increased baseline insulin levels, thats my worry with GLP-1 as CR mimetic that key longevity pathway (and IGF, etc) might actually go in the wrong direction with these HealthspanMaximalist September 10, 2024, 2:07am #7 2.2% is quite a large A1C reduction (although the sample size was not that big)
We have to be cautious that some reported active natural compounds might actually be PAINS
So, is one superior to the other
